MétaCan
Menu
← Back to cohort
Record W2904237382 · doi:10.3747/co.25.4213

Developing a Model of a Patient-Group Pathway to Accessing Cancer Clinical Trials in Canada

2018· article· en· W2904237382 on OpenAlexafffundvenueabout
Gerald Batist, S. Michaud, Dawn P. Richards, Filomena Servidio-Italiano, Barry D. Stein

Bibliographic record

VenueCurrent Oncology · 2018
Typearticle
Languageen
FieldMedicine
TopicClinical practice guidelines implementation
Canadian institutionsInstitute for Research in Immunology and CancerRobarts Clinical TrialsJewish General Hospital
FundersEli Lilly CanadaPartenariat Canadien Contre Le CancerF. Hoffmann-La RocheBristol-Myers SquibbEli Lilly and CompanyMerck CanadaInnovative Medicines Canada
KeywordsStakeholderClinical trialMedicineStakeholder engagementGeneral partnershipInclusion (mineral)Working groupAlternative medicineFamily medicinePublic relationsMedical educationPolitical sciencePsychologyPathology

Abstract

fetched live from OpenAlex

Background: Colorectal Cancer Canada, in partnership with a Scientific Advisory Committee, is developing a Canadian Patient Group Pathway to Accessing Cancer Clinical Trials ("Pathway"). A central element of the Pathway is presented here-namely, a set of recommendations and tools aimed at each stakeholder group. Methods: A summary of the peer-reviewed and grey literature informed discussions at a meeting, held in June 2017, in which a cross-section of stakeholders reached consensus on the potential roles of patient groups in the cancer clinical trials process, barriers to accessing cancer clinical trials, best practice models for patient-group integration, and a process for developing the Pathway. Canadian recommendations and tools were subsequently developed by a small working group and reviewed by the Scientific Advisory Committee. Results: The major output of the consensus conference was agreement that the Clinical Trials Transformation Initiative (ctti) model, successfully applied in the United States, could be adapted to create a Canadian Pathway. Two main differences between the Canadian and American cancer clinical research environments were highlighted: the effects of global decision-making and systems of regulatory and funding approvals. The working group modified the ctti model to incorporate those aspects and to reflect Canadian stakeholder organizations and how they currently interact with patient groups. Conclusions: Developing and implementing a Canadian Pathway that incorporates the concepts of multi-stakeholder collaboration and the inclusion of patient groups as equal partners is expected to generate significant benefits for all stakeholders. The next steps to bring forward a proposed Pathway will involve engaging the broader cancer research community. Clinical trial sponsors will be encouraged to adopt a Charter recognizing the importance of including patient groups, and to support the training of patient groups through an independent body to ensure quality research partners. Integration of patient groups into the process of developing "real world" evidence will be advanced by a further consensus meeting being organized by Colorectal Cancer Canada for 6-7 November 2018.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.026
metaresearch head score (Gemma)0.043
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Qualitative · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: none
Teacher disagreement score0.143
Threshold uncertainty score0.741

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0260.043
Meta-epidemiology (narrow)0.0010.001
Meta-epidemiology (broad)0.0000.002
Bibliometrics0.0020.003
Science and technology studies0.0110.008
Scholarly communication0.0140.005
Open science0.0050.009
Research integrity0.0050.004
Insufficient payload (model declined to judge)0.0130.002

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.834
GPT teacher head0.685
Teacher spread0.149 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designQualitative
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations2
Published2018
Admission routes4
Has abstractyes

Explore more

Same venueCurrent Oncology→Same topicClinical practice guidelines implementation→French-language works237,207→